Product Portfolio

Nature-backed probiotic solutions

AB-BIOTICS
Part of KANEKA Corporation

Why AB-BIOTICS?

We offer a diversified product range to meet the needs of our partners

Research and development of a vast generation of natural probiotic strains formulated not only to meet therapeutic needs but also to maintain human health.

Unique strains with characterized mechanism of action

1. Collection of hundreds of bacteria strains, creating a private strain bank. Microbiota samples taken from non-industrialised societies (human resident bacteria).
2. Characterisation of the strains' mechanism of action, after selecting those with outstanding phenotypes.
3. **Patent protection.**

Clinically-proven probiotic solutions

1. Development of probiotic blends with relevant medical applications for every stage of life.
2. Complete *in vitro* and *in vivo* investigation process.
3. Clinical validation in humans. Gold standard randomised, double-blind, placebo-controlled clinical trials.

Ready-to-market products

1. Generation and manufacturing of the final product concept (dose, delivery form, formulation and posology), following all quality and regulatory processes. Choose from a range of different formulations and final applications.
2. Development of a value proposition and positioning of the final product, taking into consideration specific market needs and competitors.
3. Proven safety and efficacy.
4. **Private labelling; use your brand on your final, individualized product.**

Therapeutic areas and finished products

Gastrointestinal health

i3.1®
P. acidilactici KABP™ 021
L. plantarum KABP™ 022
L. plantarum KABP™ 023

AB-DIGEST
B. longum KABP™ 042
P. pentosaceus KABP™ 041
L. rhamnosus GG

Pediatric health

AB-KOLICARE®
B. longum KABP™ 042
P. pentosaceus KABP™ 041

AB-DIGEST kids
B. longum KABP™ 042
P. pentosaceus KABP™ 041
L. rhamnosus GG

Oral health

AB-DENTALAC®
L. plantarum KABP™ 051
L. brevis KABP™ 052
P. acidilactici KABP™ 053

AB-IMPLALAC
P. acidilactici CECT 8904
P. pentosaceus CECT 8905
P. acidilactici CECT 8906

Cardiometabolic health

LipiGO®
Saccharomyces cerevisiae
postbiotic (BGCC extract)

AB-LIFE®
L. plantarum KABP™ 011
L. plantarum KABP™ 012
L. plantarum KABP™ 013

Immune health

AB-DR7
L. plantarum DR7

INNERIM®
L. plantarum KABP™ 031
L. plantarum KABP™ 032

AB21®
L. plantarum KABP™ 033
L. plantarum KABP™ 022
L. plantarum KABP™ 023
P. acidilactici KABP™ 021

Brain health

MINDBIOME®
L. plantarum DR7

MINDBIOME® PLUS
L. brevis KABP™ 052
L. plantarum KABP™ 023

Women's health

AB-CYSCARE
L. plantarum KABP™ 062
L. plantarum KABP™ 063

GYNTIMA®
L. plantarum KABP™ 061

Skin health

AB-SAKEI 65®
L. sakei proBio 65

AB-SKINBIOTIC
L.rhamnosus KABP™ 071
Arthrospira platensis

Eye health

AB-PROTEARS®
L. sakei proBio 65

Our probiotic strains

Pediococcus acidilactici KABP™ 021	CECT 7483	→ **Antagonistic activity** against IBS-related bacteria → Synthesis of SCFA (**acetate**)
Lactiplantibacillus plantarum KABP™ 022	CECT 7484	→ Enhancement of the **intestinal barrier** via synthesis of poly-P granules → Reduction of inflammation through the production of **acetylcholine** → **Antagonistic activity** against IBS-related pathogenic bacteria → Synthesis of SCFA (**acetate**)
Lactiplantibacillus plantarum KABP™ 023	CECT 7485	
Lacticaseibacillus rhamnosus GG	ATCC 531033	→ Strong adhesive capacity to the intestinal epithelium → Modulation of the innate and adaptative immune responses → Synthesis of **p40 and p75 proteins**, that protect the epithelial barrier, enhance intestinal cells' function and promote the production of IgA → Antagonistic activity against gastrointestinal tract pathogens
Bifidobacterium longum KABP™ 042	CECT 7894	→ Antagonistic activity against colic-related pathogenic bacteria → Digestion of HMOs, supporting a **healthy gut colonisation** → Homofermentative metabolism (no CO_2 production) → Synergic protection of intestinal epithelial barrier (tight junctions)
Pediococcus pentosaceus KABP™ 041	CECT 8330	→ Induction of anti-inflammatory molecules (**IL-10**) → Homofermentative metabolism (no CO_2 production) → Antagonistic activity against colic-related pathogenic bacteria → Synergic protection of intestinal epithelial barrier (tight junctions)
Lactiplantibacillus plantarum KABP™ 051	CECT 7481	→ **Good aggregation and adhesion** to tissues in the oral cavity, preventing overgrowth of undesirable bacteria → Good tolerance against lysozyme and most antiseptics found in mouthwashes → **Antagonistic activity** against oral pathogenic bacteria → Low production of acid and malodorous compounds
Levilactobacillus brevis KABP™ 052	CECT 7480	
Pediococcus acidilactici KABP™ 053	CECT 8633	

IBS: Irritable Bowel Syndrome. SCFA: short chain fatty acids. poly-P granules: polyphosphate granules. IgA: immunoglobulin A. HMOs: human milk oligosaccharides. IL-10: interleukin 10

Our probiotic strains

Lactiplantibacillus plantarum KABP™ 011	CECT 7527	→ Modification of the enterohepatic cycle through a high **BSH activity** → Capacity to capture intestinal cholesterol, promoting its excretion
Lactiplantibacillus plantarum KABP™ 012	CECT 7528	
Lactiplantibacillus plantarum KABP™ 013	CECT 7529	
Saccharomyces cerevisiae postbiotic	BGCC extact	→ Specific **binding to saturated fats**, limiting its absorption through the intestinal wall
Lactobacillus plantarum DR7®	KCTC 13909BP	→ Regulation of neuroactive molecules, with effects on the **serotonin-kynurenine** pathway and **dopamine-norepinephrine** pathway → Modification of gut bacteria concentrations affecting the **gut-brain axis** → Improvement of anti-inflammatory (IL-10) versus pro-inflammatory (TNF-α, IFN-γ) signals → Reduction of stress-associated molecules (**cortisol**) plasma levels. → Antioxidative properties → **Direct antagonistic activity** against pathogens linked with URTIs
Levilactobacillus brevis KABP™ 052	CECT 7480	→ Production of GABA, dopamine and acetylcholine modulating the **gut-brain** axis
Lactiplantibacillus plantarum KABP™ 031	CECT 7315	→ Synthesis of acetate linked with an increase in IgA (**increased immune protection**) and induction of T-cells → Modulation of several anti and proinflammatory cytokines → Reduction of TGF-β1, **, improving immune response**
Lactiplantibacillus plantarum KABP™ 032	CECT 7316	

BSH: bile salt hydrolase. SCFA: short chain fatty acids. BGCC: β-glucan and chitin chitosan. IL-10: interleukin 10. TNF-α: tumor necrosis factor alpha. IFN-γ: interferon gamma. URTIs: upper respiratory tract infections.
GABA: gamma-aminobutyric acid. IgA: immunoglobulin A. TGF-β1: transforming growth factor beta 1

Our probiotic strains

Lactiplantibacillus plantarum KABP™ 033	CECT 30292	→ High plnG gene activity, boosting the adaptative immune response by direct cross-talk with dendritic cells → Increased production of specific antibodies
Latilactobacillus sakei proBio 65	KCTC 10755BP	→ Stimulation of **regulatory lymphocites**, linked with an increased production of several cytokines (IL-10, IL-12, IL-17, IFN-γ) → Reduction of chemokines associated with allergic responses and inflammatory processes
Lacticaseibacillus rhamnosus KABP™ 071	CECT 3001	→ **Normalization** of the insulin pathway, which is disregulated in acne formation → **Immunomodulatory** effects
Lactiplantibacillus plantarum KABP™ 062	CECT 8675	→ **Antagonistic activity** against uropathogenic bacteria → Survival of the vaginal environment → **Biofilm formation and acidification capacity**, preventing overgrowth of undesirable bacteria
Lactiplantibacillus plantarum KABP™ 063	CECT 8677	
Lactiplantibacillus plantarum KABP™ 061	CECT 7504	→ **Antagonistic activity** against pathogenic bacteria linked with infections such as bacterial vaginosis → High adhesion capacity to the vaginal epithelium → **Acidification capacity** preventing overgrowth of undesirable bacteria → Antagonistic activity against *Candida* spp. High resistance to simulated candidiasis vaginal environment

IL-10: interleukin 10. IL-12: interleukin 12. TNF-α: tumor necrosis factor alpha. IL-17: interleukin 17. IFN-γ: interferon gamma. LPS: lipopolysaccharide. FoxO1: forkhead box protein O1

Our probiotic blends - Gastrointestinal health

CAPSULES STICKS DROPS

i3.1®

P. acidilactici KABP™ 021
L. plantarum KABP™ 022
L. plantarum KABP™ 023

Indication

- Irritable bowel syndrome (IBS)
- Lactose intolerance
- Digestive wellbeing

Daily dose in final product: 3 billion CFU

Scientific support

1. Lorenzo-Zúñiga V, et al. i.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J. Gastroenterol. 20, 8709–8716 (2014).

2. Barraza-Ortiz DA, et al. Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study. Dig. Dis. (2020)

3. Cano-Contreras A, et al. Efficacy of probiotic i3.1 symptomatic improvement in patients with lactose intolerance. J Clin. Gastroenterol. (2020).

4. Lorén V, et al. Comparative effect of the i3.1 probiotic formula in two animal models of colitis. Probiotics Antimicrob. Proteins. 9, 71–80 (2017).

5. Perez M, et al. Derived postbiotics of a multi-strain probiotic formula clinically validated for the treatment of Irritable bowel syndrome. FASEB J. 34, 1–1 (2020).

Additional compounds: Vitamin D

SHOTS STICKS

AB-DIGEST

B. longum KABP™ 042
P. pentosaceus KABP™ 041
L. rhamnosus GG

Indication

- Diarrhea, antibiotic co-treatment
- Microbiota restoration
- Immune support

Daily dose in final product: 6 billion CFU

Scientific support*

1. Hempel S, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 9, 1959–69 (2012).

2. Szajewska H, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment. Pharmacol. Ther. 42, 1149-57 (2014).

3. Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281-288 (2017).

4. Astó E, et al. Equivalence of a novel *Lactobacillus rhamnosus* isolate to the reference ATCC53103 strain. Poster presented at SEPyP congress (2018).

Additional compounds: Inulin, Fructooligosaccharides (FOS), Zinc

*Due to the big amount of published clinical studies with *L.rhamnosus* GG, only latest, robust reviews are listed

Our probiotic blends - Pediatric health

DROPS

AB-KOLICARE®

B. longum KABP™ 042
P. pentosaceus KABP™ 041

Indication

- Infant colic
- Microbiota development

Daily dose in final product: 1 billion CFU

Scientific support

1. Chen K. et al. Infantile Colic Treated With *Bifidobacterium longum* CECT7894 and *Pediococcus pentosaceus* CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Pediatrics 0, 939 (2021).

2. Asto E et al. Probiotic Properties of *Bifidobacterium longum* KABP™ 042 and *Pediococcus pentosaceus* KABP™ 041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol* 12, (2022).

3. Santas JM, et al. *Pediococcus pentosaceus* CECT 8330 and *Bifidobacterium longum* CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharm Bio Sci. 6, 458-466 (2015).

4. Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281-288 (2017).

5. Tintore M, et al. Gut microbiota dysbiosis and role of probiotics in infant colic. Arch. Clin. Microbiol. 08, 56 (2017).

6. Dong F et al. *Pediococcus pentosaceus* CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice. *Journal of Translational Medicine 20*, 1–16 (2022).

Additional compounds: Vitamin D

SHOTS STICKS DROPS

AB-DIGEST

B. longum KABP™ 042
P. pentosaceus KABP™ 041
L. rhamnosus GG

Indication

- Diarrhea, antibiotic co-treatment
- Microbiota restoration
- Immune support

Daily dose in final product: 6 billion CFU

Scientific support*

1. Szajewska H, et al. Meta-analysis: *Lactobacillus* GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 38, 467–76 (2013).

2. Szajewska H, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 42, 1149–57 (2015).

3. Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281-288 (2017).

4. Asto E et al. Equivalence of a novel *Lactobacillus rhamnosus* isolate to the reference ATCC53103 strain. Poster presented at SEPyP congress (2018)

Additional compounds: Inulin, Fructooligosaccharides (FOS), Zinc

*Due to the big amount of published clinical studies with *L.rhamnosus* GG, only latest, robust reviews are listed

Our probiotic blends - Oral health

TABLETS VIALS GUMS

AB-DENTALAC®

L. plantarum KABP™ 051
L. brevis KABP™ 052
P. acidilactici KABP™ 053

Indication

- Gingivitis, periodontitis
- Protection after oral surgery
- Prevention of caries, halitosis

Daily dose in final product: 1 billion CFU

Scientific support

1. Nart J et al. Oral colonization by *Levilactobacillus brevis* KABP™ 052 and Lactiplantibacillus plantarum KABP™ 051: A Randomized, Double-Blinded, Placebo-Controlled Trial (Pilot Study). *J Clin Exp Dent* 13, 433–439 (2021).

2. Montero E, et al. Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: A randomized controlled clinical trial. J. Clin. Periodontol. 44, 708–716 (2017).

3. Ferrés-Amat E, et al. Probiotics diminish the post-operatory pain following mandibular third molar extraction: A randomised double-blind controlled trial (pilot study). Benef. Microbes 11, 631–639 (2020).

4. Calabuig RP, et al. Oral probiotic reduces pain after third molar extraction procedure. Poster presented at SEPyP congress (2019).

5. Bosch M, et al. Isolation and characterization of probiotic strains for improving oral health. Arch Oral Biol. 57, 539-349 (2012).

Additional compounds: Vitamin D

TABLETS VIALS

AB-IMPLALAC

P. acidilactici CECT 8904
P. pentosaceus CECT 8905
P. acidilactici CECT 8906

Indication

- Peri-implantitis prevention
- Oral microbiota balance

Daily dose in final product: 1 billion CFU

Scientific support

1. Clinical trial on-going: evaluation of the improvement of peri-implantitis state in implants treated with probiotics.

Additional compounds: Vitamin D

Our probiotic blends - Cardiometabolic health

CAPSULES STICKS DROPS

AB-LIFE®

***L. plantarum* KABP™ 011**
***L. plantarum* KABP™ 012**
***L. plantarum* KABP™ 013**

Indication

- Hypercholesterolemia
- Hypertriglyceridemia

Daily dose in final product: 1.2 billion CFU

Scientific support

1. Fuentes MC, et al. A randomized clinical trial evaluating a proprietary mixture of *Lactobacillus plantarum* strains for lowering cholesterol. Med. J. Nutrition Metab. 9, 125–135 (2016).

2. Espadaler J, et al. Demographic and clinical characteristics influencing the effects of a cholesterol-lowering probiotic. Ann. Nutr. Metab. 74, 1–31 (2019).

3. Bosch M, et al. *Lactobacillus plantarum* CECT 7527, 7528 and 7529: Probiotic candidates to reduce cholesterol levels. J. Sci. Food Agric. 94, 803–809 (2014).

4. Kim DH, et al. Effect of mixture of *Lactobacillus plantarum* CECT 7527, 7528, and 7529 on obesity and lipid metabolism in rats fed a high-fat diet. J. Korean Soc. Food Sci. Nutr. 43, 1484–1490 (2014).

5. Mukerji P, et al. Safety evaluation of AB-LIFE®: Antibiotic resistance and 90-day repeated-dose study in rats. Food Chem. Toxicol. 92, 117–128 (2016).

6. Guerrero-Bonmatty, R et al. A Combination of *Lactoplantibacillus plantarum* strains CECT7527, CECT7528, and CECT7529 plus monacolin K reduces blood cholesterol: Results from a randomized, double-blind, placebo-controlled Study. Nutrients 2021, Vol. 13, Page 1206 13, 1206 (2021).

Additional compounds: Vitamin B1, Omega 3 (alpha linolenic acid)

STICKS

LipiGO®

***Saccharomyces cerevisiae* postbiotic (BGCC extract)**

Indication

- Prevents rebound effect
- Safe weight loss
- Overweight and type I obesity

Daily dose in final product: 3000 mg

FINALIST NUTRA INGREDIENTS ASIA AWARDS 2020

WINNER NUTRA INGREDIENTS AWARDS 2022

Scientific support

1. Santas J, et al. Effect of a polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) in body weight loss: randomised, double-blind, placebo-controlled clinical trial in overweight and obese adults. J Sci Food Agric. 97, 4250–7 (2017).

2. Valero-Pérez, M. et al. Regular consumption of Lipigo® promotes the reduction of body weight and improves the rebound effect of obese people undergo a comprehensive weight loss program. Nutrients 2020, Vol. 12, Page 1960 12, 1960 (2020).

3. Santas J, et al. Polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) increases fatty acid and neutral sterol excretion in guinea pigs fed with hypercholesterolemic diets. Eur J Lipid Sci Technol. 119, 17001-04 (2017).

Our probiotic blends - Brain health

CAPSULES STICKS

MINDBIOME®

L. plantarum DR7

Indication

- Stress and anxiety
- Emotional well-being
- Memory and cognition

Daily dose in final product: 1 billion CFU

Scientific support

1. Chong HX, et al. *Lactobacillus plantarum* DR7 alleviates stress and anxiety in adults: A randomised, double-blind, placebo-controlled study. Benef. Microbes 10, 355–373 (2019).

2. Liu G, et al. *Lactobacillus plantarum* DR7 modulated bowel movement and gut microbiota associated with dopamine and serotonin pathways in stressed adults. Int. J. Mol. Sci. 21, 4608 (2020).

3. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and Metabolites of d-Galactose-Induced Aging Rats Fed with High-Fat Diet. Probiotics Antimicrob. Proteins 12, 545–562 (2020).

Additional compounds: Magnesium

CAPSULES STICKS

MINDBIOME® PLUS

L. brevis KABP™ 052
L. plantarum KABP™ 023

Indication

- Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD)
- Concentration and focus

Daily dose in final product: 1 billion CFU

Scientific support

1. Clinical trial on-going: Food intervention in children suffering from autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD): A randomized, double-blind, placebo-controlled study.

2. Clinical trial on-going: Randomized clinical trial to analyse the effect of a probiotic mixture on stress response and cognitive and emotional variables.

3. Pre-clinical trial in mouse model of induced cognitive deficit to test the probiotic effect on cognitive dysfunction. Manuscript under preparation.

Additional compounds: Magnesium, Vitamin D, Vitamin B

Our probiotic blends - Immune health

CAPSULES STICKS DROPS

AB-DR7

L. plantarum DR7

Indication

- Upper respiratory tract infections (URTIs)
- Respiratory health

Daily dose in final product: 1 billion CFU

Scientific support

1. Chong HX, et al. *Lactobacillus plantarum* DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study. J. Dairy Sci. 102, 4783–4797 (2019).

2. Altadill T, et al. Does *Lactoplantibacillus plantarum* DR7 reduce days of upper respiratory tract infections and fever? A post-hoc analysis of a randomized, placebo-controlled trial. FASEB Journal (2021).

3. Baud D, et al. Using probiotics to flatten the curve of coronavirus disease COVID-2019. Pandemic. Front. Public Heal. 8, (2020).

4. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and metabolites of d-galactose-induced aging rats fed with high-fat diet. Probiotics Antimicrob. Proteins. 12, 545–562 (2020).

Additional compounds: Vitamin D, C, Zinc

CAPSULES STICKS DROPS

INNERIM®

L. plantarum KABP™ 031
L. plantarum KABP™ 032

Indication

- Immunity support
- Immunosenescence prevention

Daily dose in final product: 1 billion CFU

Scientific support

1. Mañé J, et al. A mixture of *Lactobacillus plantarum* CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. Nutr. Hosp. 26, 228-235 (2011).

2. Bosch M, et al. El consumo del probiótico *Lactobacillus plantarum* CECT 7315/7316 mejora el estado de salud general en personas de edad avanzada. Nutr. Hosp. 26, 642-645 (2011).

3. Bosch M, et al. *Lactobacillus plantarum* CECT 7315 and CECT 7316 stimulate immunoglobulin production after influenza vaccination in elderly Nutr. Hosp. 27, 504–509 (2012).

4. Vilahur G, et al. *Lactobacillus plantarum* CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response. Eur. J. Nutr. 54, 1161–1171 (2015).

5. Bosch M, et al. Probiotic properties of *Lactobacillus plantarum* CECT 7315 and CECT 7316 isolated from faeces of healthy children. Lett. Appl. Microbiol. 54, 240–246 (2012).

Additional compounds: Vitamin B_9, B_6, B_{12}, C, A, Zinc, Selenium

Our probiotic blends - Immune health

CAPSULES STICKS DROPS

WINNER NUTRA INGREDIENTS AWARDS 2022

For more info visit:

ab21probiotic.com

AB21®

L. plantarum KABP™ 033
L. plantarum KABP™ 022
L. plantarum KABP™ 023
P. acidilactici KABP™ 021

Daily dose in final product: 2 billion CFU

Additional compounds: Vitamin D

Indication

- Mild to moderate diagnosed COVID-19
- Increased exposure to viruses
- To potentiate immunity after vaccination

Scientific support

1. Gutiérrez-Castrellón, P. et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. *Gut Microbes* 14, (2022) .
2. Gutiérrez-Castrellon, P et al. Probiotic Effect on SARS-CoV2 Immunity Is Associated to Type-1 Interferons: A Post-Hoc Analysis of a Randomized, Placebo-Controlled Trial. Experimental Biology Congress, April 2022.

Our probiotic blends - Skin health

CAPSULES STICKS CREAM

AB-SAKEI 65®

L. sakei proBio 65

Indication

- Atopic dermatitis
- Skin redness and discomfort

Daily dose in final product: 5 billion CFU

Scientific support

1. Woo SI, et al. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. Ann. Allergy, Asthma Immunol. 104, 343–348 (2010).

2. Park SB, et al. Effect of emollients containing vegetable-derived lactobacillus in the treatment of atopic dermatitis symptoms: Split-body clinical trial. Ann. Dermatol. 26, 150–155 (2014).

3. Rather IA, et al. Oral administration of live and dead cells of *Lactobacillus sakei* proBio65 alleviated atopic dermatitis in children and adolescents: a randomized, double-blind, and placebo-controlled Study. Probiotics Antimicrob. Proteins (2020).

4. Lim J, et al. Immune-modulating characteristics of *Lactobacillus sakei* proBio65 isolated from Kimchi. Korean J. Microbiol. Biotechnol. 39, 313-316 (2011).

5. Kim JY, et al. Atopic dermatitis-mitigating effects of new *Lactobacillus* strain, *Lactobacillus sakei* probio 65 isolated from Kimchi. J. Appl. Microbiol. 115, 517–526 (2013).

Additional compounds: Zinc, Niacin, Vitamin C

CAPSULES STICKS

AB-SKINBIOTIC

L.rhamnosus KABP™ 071
Arthrospira platensis

Indication

- Mild to moderate acne
- Skin microbiota balance

Daily dose in final product: 4 billion CFU

Scientific support

1. Clinical trial on-going: Effects of the administration of a probiotic formula in acne patients. A randomized, double blind, placebo-controlled study.

Additional compounds: None

Our probiotic blends - Women's health

CAPSULES

AB-CYSCARE

L. plantarum KABP™ 062
L. plantarum KABP™ 063

Indication

- Urinary tract infections (UTIs)
- Urogenital microbiota balance

Daily dose in final product: 1 billion CFU

Scientific support*

1. Simón E, et al. Screening of *Lactobacilli* strains of human origin candidates for the prevention of urinary tract infections. Ann. Nutr. Metab. 74, 1–31 (2019).

2. Padayatty SJ, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 22, 18-35 (2003)

3. Ochoa-Brust GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylacticagent during pregnancy. Acta. Obstet. Gynecol. Scand. 86, 783-7 (2007).

4. Wang CH, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 172, 988-96 (2012).

5. Salo J, et al. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized controlled trial. Clin Infect Dis. 54, 340-6 (2012).

Additional compounds: Cranberry extract, Vitamin C



VAGINAL TABLETS

CAPSULES

GYNTIMA®

L. plantarum KABP™ 061

Indication

- Vaginal candidiasis
- Vaginal microbiota balance

Daily dose in final product: 0.1 billion CFU

Scientific support

1. Palacios S, et al. Is it posible to prevent recurrent vulvovaginitis? Role of *Lactobacillus plantarum* I1001 (CECT7504). Eur J Clin Microbiol. Infect. Dis. 35, 1701-8 (2016).

2. Clinical trial on-going: Interventional study to evaluate the effect of the oral administration of L. plantarum on vaginal microbiota.

Additional compounds: Zinc, Biotin, Selenium

*Clinical trials and meta-analyses of AB-CYSCARE added compounds (cranberry extract, vitamin C) are also listed.

Our probiotic blends - Eye health

EYE DROPS

AB-PROTEARS®

L. sakei proBio 65

Indication

- Ocular irritation
- Allergies and inflammation of the eye surface

Daily dose in final product: 1 billion CFU

Scientific support

1. Clinical trial on-going

2. *In vivo* testing for skin sensibilization and ocular irritation

Our available formats

CAPSULES

- 5 capsules
- 15 capsules
- 30 capsules
- bulk

MICROENCAPSULATED CAPSULES

- 5 capsules
- 15 capsules
- 30 capsules
- bulk

Probiotics microencapsulated with PROBS® technology, to ensure stability when mixed with specific ingredients like Omega 3 oil or Cranberry extract

STICKS

- 2 sticks
- 20 sticks
- 30 sticks
- 42 sticks
- 90 sticks
- bulk

SHOTS

- 5 shots
- 7 shots
- 10 shots
- bulk

BLUE OR INLINE DROPPER

- 3ml shots
- 8ml shots
- 10ml shots
- bulk

Our available formats

EYE DROPPER

- 3ml dropper
- 8ml dropper

ORAL GUMS

ORAL TABLETS

- 5 tablets
- 10 tablets
- 15 tablets
- 30 tablets
- 60 tablets
- bulk

VIAL

- 3ml
- 8ml shots
- 10ml shots
- bulk

VAGINAL TABLETS

- 7 tablets + 1 applicator
- 7 tablets no applicator
- 7 tablets blister in bulk
- 7 tablets + 7 applicator

Quality standards

Patented products

Clinically-proven and safe

Organic strains, natural origin

Allergen-free

Qualified Presumption of Safety status (EFSA)

Not modified genetically

Generally Recognised as Safe (FDA) and/or Natural Product Number (Health Canada)

As a leading B2B company with global presence:

We support our partners throughout product lifespan

R&D, market access and marketing specialists. Complete, personalised support every step of the way

We adapt to our partners' aspirations and needs

Co-development of probiotic solutions following market trends

AB-BIOTICS
Part of KANEKA Corporation

www.ab-biotics.com

04.22